Skip to main content
. 2022 Feb 25;31(14):2452–2461. doi: 10.1093/hmg/ddac024

Table 3.

Enrichment of select canonical pathways and corresponding protein components associated with the ABO rs657152 variant

Pathway Pathway components Symbol Expression Log ratio Expression P-value
IL-15 suppression
Macrophage colony-stimulating factor 1 receptor CSF1R 0.033 2.2E-07
Insulin-like growth factor 1 receptor IGF1R -0.03 6.9E-11
Ephrin type-B receptor 4 EPHB4 -0.034 2.0E-11
Vascular endothelial growth factor receptor 3 FLT4 -0.074 1.2E-15
* Hepatocyte growth factor receptor MET -0.056 1.2E-35
* Ephrin type-A receptor 4 EPHA4 -0.058 1.0E-52
Vascular endothelial growth factor receptor 2 KDR -0.065 1.7E-56
Insulin receptor INSR -0.108 2.7E-65
Tyrosine-protein kinase receptor Tie-1 TIE1 0.09 2.9E-85
STAT3 signaling
Interleukin-6 receptor subunit beta IL6ST -0.019 2.9E-09
Insulin-like growth factor 1 receptor IGF1R -0.03 6.9E-11
Vascular endothelial growth factor receptor 3 FLT4 -0.074 1.2E-15
Vascular endothelial growth factor receptor 2 KDR -0.065 1.7E-56
Interleukin-3 receptor subunit alpha IL3RA -0.127 4.4E-63
Insulin receptor INSR -0.108 2.7E-65
NF-κB signaling
Insulin-like growth factor 1 receptor IGF1R -0.03 6.9E-11
Vascular endothelial growth factor receptor 3 FLT4 -0.074 1.2E-15
Vascular endothelial growth factor receptor 2 KDR -0.065 1.7E-56
Insulin receptor INSR -0.108 2.7E-65

*Significantly associated with incident hospitalized respiratory infection (P < 5.9 × 10−4) in prospective analysis (Fig. 1).

Significantly associated with incident hospitalized pneumonia (P < 5.9 × 10−4) in prospective analysis (Fig. 1).